(Total Views: 590)
Posted On: 05/08/2021 10:40:15 AM
Post# of 148903
My answer to the moron "Out of Ignorance" (which is an oxymoron) in SA:
Quote:
I saw a link to this and came to read for chuckles ...
Remember vividly back in February 2019 " What To Do When It's Too Good To Be True" and Oct. 25, 2019 "CytoDyn: When More Is Less " articles.
I was doing my research in CYDY and did not see a morsel of Science behind your opinions. And that is your problem. You document opinionated facts but have little comments/discussion on the SCIENCE.
The way I look at it is to ask the question: does the drug works? and then: can the company bring the ball to the goal post ??
After reading several papers on the moa of CCR5 and Leronlimab I concluded that this was the real thing. Loaded upon CYDY shares during 2019 ... and have been generously rewarded.
BTW, since you wrote your October 2 article price is up 855.9%.
What I am trying to say OOI is that you are catching the tiger by the tail. It is easy to comment on financial situations of pre-revenue companies, or CEO's characterizations, or filing failures, or missing deadlines. That is fine. But is more difficult to read papers and ascertain if something might work in the therapeutic benefit arena.
Eventually this is where the battles will be fought. Not only for CYDY but for all biotech companies.
The question for you is: Do you think the science of CCR5 antagonism works in HIV, Cancer, NASH, COVID ??
If the answer is yes load up !!!. If the answer is no, don't waste time writing articles about CYDY unless, of course, you want to impact the public into your current "trading" direction or gain some fees for publication.
If you need some help answering this question I can send you some good papers, attaching the link to one of recent publication.
pubmed.ncbi.nlm.nih.gov/...
Now, indeed the financials of a company are relevant. This is the Risk part of the equation. To me CytoDyn Risk/Reward is very compelling. You have to forgive me for saying this from the perspective of somebody that has a very substantial profit (in paper) already (thankfully I did not take seriously your comments of 2019).
I am not selling a single share until somebody convinces me that Vyrologix does not work.
(23)
(0)Scroll down for more posts ▼
